Inhibition of Aquaporin-4 Improves the Outcome of Ischaemic Stroke and Modulates Brain Paravascular Drainage Pathways

Int J Mol Sci. 2017 Dec 23;19(1):46. doi: 10.3390/ijms19010046.

Abstract

Aquaporin-4 (AQP4) is the most abundant water channel in the brain, and its inhibition before inducing focal ischemia, using the AQP4 inhibitor TGN-020, has been showed to reduce oedema in imaging studies. Here, we aimed to evaluate, for the first time, the histopathological effects of a single dose of TGN-020 administered after the occlusion of the medial cerebral artery (MCAO). On a rat model of non-reperfusion ischemia, we have assessed vascular densities, albumin extravasation, gliosis, and apoptosis at 3 and 7 days after MCAO. TGN-020 significantly reduced oedema, glial scar, albumin effusion, and apoptosis, at both 3 and 7 days after MCAO. The area of GFAP-positive gliotic rim decreased, and 3D fractal analysis of astrocytic processes revealed a less complex architecture, possibly indicating water accumulating in the cytoplasm. Evaluation of the blood vessels revealed thicker basement membranes colocalizing with exudated albumin in the treated animals, suggesting that inhibition of AQP4 blocks fluid flow towards the parenchyma in the paravascular drainage pathways of the interstitial fluid. These findings suggest that a single dose of an AQP4 inhibitor can reduce brain oedema, even if administered after the onset of ischemia, and AQP4 agonists/antagonists might be effective modulators of the paravascular drainage flow.

Keywords: aquaporin-4 inhibition; basement membranes; ischemic stroke; non-reperfusion ischemia; paravascular drainage.

MeSH terms

  • Albumins / metabolism
  • Animals
  • Apoptosis / drug effects
  • Aquaporin 4 / antagonists & inhibitors*
  • Aquaporin 4 / metabolism
  • Arteries / drug effects
  • Arteries / pathology
  • Brain / blood supply
  • Brain / pathology*
  • Brain Ischemia / complications
  • Brain Ischemia / drug therapy
  • Brain Ischemia / pathology*
  • Brain Ischemia / physiopathology
  • Caspase 3 / metabolism
  • Disease Models, Animal
  • Drainage*
  • Edema / complications
  • Edema / pathology
  • Extravasation of Diagnostic and Therapeutic Materials / complications
  • Extravasation of Diagnostic and Therapeutic Materials / drug therapy
  • Extravasation of Diagnostic and Therapeutic Materials / pathology
  • Gliosis / complications
  • Gliosis / pathology
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / pathology*
  • Infarction, Middle Cerebral Artery / physiopathology
  • Motor Activity / drug effects
  • Niacinamide / analogs & derivatives
  • Niacinamide / pharmacology
  • Niacinamide / therapeutic use
  • Stroke / complications
  • Stroke / drug therapy
  • Stroke / pathology*
  • Stroke / physiopathology
  • Thiadiazoles / pharmacology
  • Thiadiazoles / therapeutic use
  • Treatment Outcome

Substances

  • 2-(nicotinamide)-1,3,4-thiadiazole
  • Albumins
  • Aquaporin 4
  • Thiadiazoles
  • Niacinamide
  • Caspase 3